Table 2 Relationship between circRIP2 level and clinical characteristics in bladder cancer
From: circRIP2 accelerates bladder cancer progression via miR-1305/Tgf-β2/smad3 pathway
Total | Patients | Expression of circRIP2 | ||
|---|---|---|---|---|
High | Low | p | ||
Age (mean) | 53.21 | 51.32 | 50.27 | 0.713 |
Gender | ||||
Male | 46 | 20 | 26 | 0.614 |
Female | 12 | 5 | 7 | |
Tumor stage | ||||
Tis/Ta/T1 | 33 | 13 | 20 | 0.038 |
T2 | 16 | 8 | 8 | |
T3/T4 | 9 | 4 | 5 | |
Grade | ||||
High | 34 | 9 | 25 | 0.002 |
Low | 24 | 16 | 8 | |
Number of tumors | ||||
Solitary | 41 | 22 | 19 | 0.584 |
Multiple | 17 | 3 | 14 | |
Metastasis | ||||
N0 M0 | 28 | 17 | 11 | 0.012 |
N1 M0 | 18 | 8 | 10 | 0.009 |
N1 M1 | 12 | 0 | 12 | |
Follow-up(month, mean) | 33.23 | 31.83 | 33.67 | 0.024a |